152
Views
8
CrossRef citations to date
0
Altmetric
Letter to the Editor

Acute kidney injury in patients using amikacin in an era of carbapenem-resistant bacteria

, , , , &
Pages 869-871 | Received 05 Jun 2016, Accepted 13 Jun 2016, Published online: 08 Jul 2016

References

  • Papadimitriou-Olivgeris M, Marangos M, Christofidou M, et al. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis. 2014;46:642–648.
  • Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15:pii:19711.
  • Carbonne A, Thiolet JM, Fournier S, et al. Control of a multi-hospital outbreak of KPC-producing Klebsiella pneumoniae type 2 in France, September to October 2009. Euro Surveill. 2010;15:pii:19734.
  • Papadimitriou-Olivgeris M, Marangos M, Fligou F, et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother. 2012;67:2976–2981.
  • Bagshaw SM, George C, Bellomo R, et al. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008;23:1569–1574.
  • Tuon FF, Rigatto MH, Lopes CK, et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014;43:349–352.
  • Rigatto MH, Oliveira MS, Perdigao-Neto LV, et al. Renal failure in patients treated with colistin versus polymyxin B: a multicenter prospective cohort study. Antimicrob Agents Chemother. 2016;60:2443–2449.
  • Kwon KH, Oh JY, Yoon YS, et al. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: incidence of nephrotoxicity and outcomes. Int J Antimicrob Agents. 2015;45:605–609.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.